DGAP-Adhoc: CANCOM SE: Preliminary figures for first quarter 2022 show revenue down 10.8 percent but EBITDA up 6.2 percent. Executive Board lowers forecast for 2022.
2022. május 03., kedd, 19:58
DGAP-Ad-hoc: CANCOM SE / Key word(s): Quarter Results/Change in Forecast CANCOM SE: Preliminary figures for first quarter 2022 show revenue down 10.8 percent but EBITDA up 6.2 percent. Executive Board lowers forecast for 2022. Munich, Germany, 3 May 2022 - According to the preliminary figures available today, the CANCOM Group achieved Group revenue of € 300.9 million in the first quarter of 2022. This corresponds to a decline of 10.8 percent compared to the same period last year (prior year: € 337.2 million). In contrast, Group gross profit rose by 4.3 percent to € 109.5 million in the first quarter of 2022 (prior year: € 104.9 million) and also Group EBITDA was 6.2 percent higher than the prior year"s figure at € 27.2 million (prior year: € 25.6 million). The EBITDA margin for the first quarter of 2022 improved accordingly to 9.0 percent (prior year: 7.6 percent). At € 17.3 million, Group EBITA in the first quarter of 2022 was above the prior year"s figure, too (prior year: €16.9 million). Due to the fact that, contrary to expectations, the supply chain situation is not improving but worsening, in particular due to permanent lockdowns in Asia, as well as the macroeconomic environment, the Executive Board of CANCOM SE is changing the annual forecast for some key financial figures for the financial year 2022. The full interim announcement of CANCOM Group for the first quarter of 2022 will be published on 12 May 2022 on the website www.cancom.de in the Investors section. Notifying Company: Contact / Notifying person: Note on Alternative Performance Measures:
|
Language: | English |
Company: | CANCOM SE |
Erika-Mann-Straße 69 | |
80636 Munich | |
Germany | |
Phone: | +49-(0)89/54054-0 |
Fax: | +49-(0)89/54054-5119 |
E-mail: | [email protected] |
Internet: | http://www.cancom.de |
ISIN: | DE0005419105 |
WKN: | 541910 |
Indices: | MDAX, TecDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1342659 |
End of Announcement | DGAP News Service |
1342659 03-May-2022 CET/CEST
Közzétételek - archívum
-
» Laxxon Medical to Participate in the BIO CEO & Investor Conference
[2023.02.02. 20:15]
-
» PJSC Magnitogorsk Iron and Steel Works: MMK notifies on additional extension of consent solicitation process
[2022.06.30. 13:00]
-
» Evonik Industries and Laxxon Medical see future in 3D screen printed pharmaceuticals
[2022.03.08. 15:02]
-
» Evonik und Laxxon Medical sehen Zukunftsmarkt für 3D-Druck von Tabletten
[2022.03.08. 15:02]
-
» "Game Changing" Technology Enables QR Code Integration with 3D Screen Printing
[2022.02.16. 17:31]
-
» Laxxon Medical to Participate in the 24th Annual Needham Virtual Growth Conference
[2022.01.07. 16:40]
-
» EQS-News: Focus Financial Partners Announces the Launch of Beryllus Capital in a Leading-Edge Joint Venture with the Hinduja Group
[2021.03.22. 12:45]
-
» DGAP-Adhoc: TRATON SE: TRATON und Navistar einig über Fortsetzung der Gespräche
[2020.10.16. 18:43]
-
» DGAP-Adhoc: TRATON SE: TRATON and Navistar agreement in principle
[2020.10.16. 18:43]